Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

Accreditation types: 1.5 NCPD

Expires: July 2027

To play this presentation please log in.

Don't have an account?

Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.

Faculty

Alexandra Drakaki

Faculty

Alexandra Drakaki

MD, PhD

University of California, Los Angeles, Los Angeles, California

Associate Professor of Medicine, Hematology/Oncology and Urology, Medical Director of the Genitourinary Oncology Program, Leader of the Genitourinary Research Program

Krisztina Emodi

Nurse

Krisztina Emodi

NP-C, MPH, CNS

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

GU Surgical Oncology

Margarita Huober

Nurse

Margarita Huober

MS, AGNP-C, AOCNP

Stanford Health Care, Palo Alto, California

Nurse Practitioner, Genitourinary Medical Oncology

Terence Friedlander

Moderator

Terence Friedlander

MD

Zuckerberg San Francisco General Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair, Chief, Division of Hematology/Oncology

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with urothelial bladder cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for non-muscle-invasive and muscle-invasive bladder cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

  • Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
  • Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
  • Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
  • Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
  • Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
  • Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
  • Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 1, 2026, to July 1, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS NCPD ACTIVITY
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Drakaki is on advisory committees with AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; has consulting agreements with AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; has contracted research with Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; is on data and safety monitoring boards/committees for Nektar Therapeutics; is on speakers bureaus for AstraZeneca Pharmaceuticals LP; holds stock OPTIONS — private companies in Athos Therapeutics; and has nonrelevant financial relationships with Dyania Health.

MODERATOR
Dr Friedlander is on advisory committees with Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; has consulting agreements with Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; and has contracted research with AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

Release date: July 1, 2026
Expiration date: July 1, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Balar AV et al. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors’ reply. Lancet Oncol 2021;22(9):e380. Abstract 

Chen H et al. Ocular adverse events associated with antibody-drug conjugates: A comprehensive pharmacovigilance analysis. Front Immunol 2024;15:1495137. Abstract 

Daetwyler E et al. Corticosteroid-resistant immune-related adverse events: A systematic review. J Immunother Cancer 2024;12(1):e007409. Abstract 

Daneshmand S et al. TAR-200 for bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: Results from the phase IIb SunRISe-1 study. J Clin Oncol 2025;43(33):3578-88. Abstract 

De Santis M et al. Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial. ESMO 2025;Abstract LBA108. 

De Santis M et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): Final analysis of a randomised, open-label, phase 3 trial. Lancet 2025;406(10516):2221-34. Abstract 

Galsky M et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. Genitourinary Cancers Symposium 2026;Abstract LBA630. 

Jacob JM et al. TAR-200 monotherapy in patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1. AUA 2025;Abstract. 

Kopenhafer L et al. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey. Urol Oncol 2024;42(3):70.e1-10. Abstract 

Li R et al. Bladder-sparing therapy for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection. Eur Urol 2024;86(6):516-27. Abstract 

Meeks JJ et al. The first report of disease-free survival analyses from the NIAGARA trial of perioperative durvalumab plus neoadjuvant chemotherapy in muscle-invasive bladder cancer. AUA 2025;Abstract PD39-09. 

Necchi A et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2024;25(6):720-30. Abstract 

Powles TB et al. IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. ESMO 2025;Abstract LBA8. 

Powles TB et al. A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). ESMO 2024;Abstract LBA5. 

Powles TB et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390(10):875-88. Abstract 

Powles T et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 2024;391(19):1773-86. Abstract 

Powles TB et al. IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy. ESMO 2021;Abstract 716TiP. 

Pradere B et al. Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels. Curr Opin Urol 2026;36(1):123-33. Abstract 

Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39(36):4073-126. Abstract 

Shore ND et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial. Nat Med 2025;31(8):2806-14. Abstract 

Subiela JD et al. Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy. BJU Int 2026;137(2):270-81. Abstract 

Vilaseca A et al. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations. AUA 2024;Abstract PD48-02. 

Vulsteke C et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N Engl J Med 2026;394(13):1257-69. Abstract 

Vulsteke C et al. Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. ESMO 2025;Abstract LBA2. 

Yajima S et al. Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: A systematic review and meta-analysis. JAMA Netw Open 2025;8(3):e250250. Abstract 

  • for-nurses

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Alexandra Drakaki

Faculty

Alexandra Drakaki

University of California, Los Angeles, Los Angeles, California

Associate Professor of Medicine, Hematology/Oncology and Urology, Medical Director of the Genitourinary Oncology Program, Leader of the Genitourinary Research Program

Krisztina Emodi

Faculty

Krisztina Emodi

NP-C, MPH, CNS

UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California

GU Surgical Oncology

Margarita Huober

Faculty

Margarita Huober

MS, AGNP-C, AOCNP

Stanford Health Care, Palo Alto, California

Nurse Practitioner, Genitourinary Medical Oncology

Terence Friedlander

Moderator

Terence Friedlander

MD

Zuckerberg San Francisco General Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair, Chief, Division of Hematology/Oncology

Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    MODULE 1: Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (NMIBC)

    • Current management algorithms for NMIBC; key findings informing the selection of patients with bacillus Calmette-Guérin (BCG)-unresponsive NMIBC for pembrolizumab therapy
    • Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for BCG-naïve, high-risk NMIBC
    • Available efficacy and safety data with durvalumab and sasanlimab, respectively, in combination with BCG for BCG-naïve, high-risk NMIBC
    • Potential role of anti-PD-1/PD-L1 antibodies with BCG for BCG-naïve, high-risk NMIBC

    MODULE 2: Perioperative Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)

    • Rationale for the evaluation of anti-PD-1/PD-L1 antibodies administered perioperatively for MIBC
    • Key efficacy and safety findings documented with neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for MIBC
    • FDA approval of durvalumab as a component of perioperative systemic therapy for MIBC
    • Selection of appropriate candidates with MIBC for perioperative durvalumab therapy; role, if any, for patients with preexisting autoimmune conditions, compromised renal function, et cetera

    MODULE 3: Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC

    • Pathophysiology, spectrum, frequency, severity and timing of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies
    • Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other therapies (eg, BCG, chemotherapy, enfortumab vedotin)
    • Optimal monitoring for immune-related and other potential AEs with immune checkpoint inhibitors; importance of prompt reporting of symptoms
    • Recommended algorithms for the management of various immune-related AEs by grade/severity

    MODULE 4: Novel Intravesical Therapies for Nonmetastatic UBC

    • Advantages of intravesical delivery systems to administer systemic therapies for nonmetastatic UBC
    • Available findings with the gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC in patients who are ineligible for or decline radical cystectomy
    • FDA approval of the gemcitabine intravesical system for the treatment of BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors; selection of appropriate candidates for this strategy
    • Initial safety and efficacy results with the erdafitinib intravesical delivery system TAR-210 for patients with NMIBC and select FGFR alterations
    • Ongoing Phase III evaluations of the gemcitabine intravesical system and TAR-210 for nonmetastatic UBC

    MODULE 5: Tolerability/Toxicity Profile of and Other Practical Considerations with Novel Intravesical Therapies

    • Importance of pretreatment evaluation of bladder integrity for patients about to receive intravesical therapy
    • Logistics of insertion and removal of the gemcitabine intravesical system and TAR-210
    • Incidence of urinary issues (eg, urinary frequency, urinary tract infection/pain, dysuria, micturition urgency, hematuria) related to the gemcitabine intravesical system; optimal strategies to mitigate these effects
    • Spectrum, frequency and severity of systemic toxicities with the gemcitabine intravesical system (eg, myelosuppression, other laboratory abnormalities, pneumonia); appropriate monitoring and management protocols
    • Incidence, severity and management of local and systemic side effects noted with TAR-210

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
    • Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
    • Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
    • Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
    • Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
    • Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
    • Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

    FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

    Dr Drakaki — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Nektar Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Stock OPTIONS — Private Companies: Athos Therapeutics; Nonrelevant Financial Relationships: Dyania Health.

    MODERATOR — Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.